| Title: |
Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology |
| Authors: |
Vardas, Vasileios; Ju, Julia; Christopoulou, Athina; Xagara, Anastasia; Georgoulias, Vassilis; Kotsakis, Athanasios; Alix-Panabières, Catherine; Martin, Stuart; Kallergi, Galatea |
| Contributors: |
University of Patras; University of Maryland School of Medicine; University System of Maryland; General University Hospital of Patras; University of Thessaly Volos (UTH); Hellenic Oncology Research Group (HORG); University Hospital of Larissa; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre de Recherches Ecologiques et Evolutives sur le Cancer (MIVEGEC-CREEC); Processus Écologiques et Évolutifs au sein des Communautés (PEEC); Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC); Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD Occitanie )-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD Occitanie )-Université de Montpellier (UM)-Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC); Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD Occitanie )-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD Occitanie )-Université de Montpellier (UM); European Liquid Biopsy Society Hamburg, Germany (ELBS); Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD Occitanie )-Université de Montpellier (UM); This research has been co-financed by the European Regional Development Fund of the European Union and Greek funds through the Operational Program Competitiveness Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project code: T1EDK-01562). This research was also funded by a grant from the Research Committee of the University of Patras via the “C. CARATHEODORI” program (project code: 81351), and by R01-CA154624 from the National Cancer Institute (USA). C.A.-P. is supported by la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. |
| Source: |
ISSN: 2073-4409 ; Cells ; https://hal.science/hal-04950921 ; Cells, 2023, 12 (15), pp.1940. ⟨10.3390/cells12151940⟩. |
| Publisher Information: |
CCSD; MDPI |
| Publication Year: |
2023 |
| Collection: |
Université de Montpellier: HAL |
| Subject Terms: |
metastasis; immune checkpoints; EMT; circulating tumor cells; triple-negative breast cancer; vinorelbine; [SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Metastasis, rather than the growth of the primary tumor, accounts for approximately 90% of breast cancer patient deaths. Microtentacles (McTNs) formation represents an important mechanism of metastasis. Triple-negative breast cancer (TNBC) is the most aggressive subtype with limited targeted therapies. The present study aimed to isolate viable circulating tumor cells (CTCs) and functionally analyze them in response to drug treatment. CTCs from 20 TNBC patients were isolated and maintained in culture for 5 days. Biomarker expression was identified by immunofluorescence staining and VyCap analysis. Vinorelbine-induced apoptosis was evaluated based on the detection of M30-positive cells. Our findings revealed that the CTC absolute number significantly increased using TetherChips analysis compared to the number of CTCs in patients’ cytospins (p = 0.006) providing enough tumor cells for drug evaluation. Vinorelbine treatment (1 h) on live CTCs led to a significant induction of apoptosis (p = 0.010). It also caused a significant reduction in Detyrosinated α-tubulin (GLU), programmed death ligand (PD-L1)-expressing CTCs (p < 0.001), and disruption of McTNs. In conclusion, this pilot study offers a useful protocol using TetherChip technology for functional analysis and evaluation of drug efficacy in live CTCs, providing important information for targeting metastatic dissemination at a patient-individualized level. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37566019; PUBMED: 37566019; PUBMEDCENTRAL: PMC10416943 |
| DOI: |
10.3390/cells12151940 |
| Availability: |
https://hal.science/hal-04950921; https://hal.science/hal-04950921v1/document; https://hal.science/hal-04950921v1/file/cells-12-01940-v2.pdf; https://doi.org/10.3390/cells12151940 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.536AF9FA |
| Database: |
BASE |